Figure 3.

Roadmap for GT1 hepatitis C virus (A), Roadmap for GT1 hepatitis C virus and new direct acting antivirals (B) and the “80-80” Rule (C). A: Full roadmap showing timepoints, predicted SVR based on undetectable HCVRNA at timepoints, and alternative choices at each timepoint. ¹Not eligible for shortened therapy - should complete 32 wk BPR ± 12 wk PR or complete 44 wk BPR; B: Modification of the roadmap showing that new DAAs can be considered at Treatment week (TW)4 or TW8 if HCVRNA is positive; C: Main points of the roadmap showing that if HCVRNA is negative at TW4 (on PR) or 8 (on BPR) then there is > 80% SVR. If HCVRNA is positive at week 4, then there is 41.7% SVR if 48 wk PR is continued, but at week 8, if HCVRNA is positive while on BPR then the possibility of SVR is 35%-41.2%. HCV: Hepatitis C virus; PR: Pegylated interferon and ribavirin; SVR: Sustained virological response.